June 2, 2010 โ Key research on new diagnostic uses for cardiac ultrasound will be presented at the American Society of Echocardiography (ASE) 21st Annual Scientific Sessions June 12-15, in San Diego. Leading experts in cardiology will present and discuss the latest clinical and research developments in adult and pediatric echocardiography. Among the key presentations are:
June 2, 2010 โ Heart failure patients whose treatment was guided by pulmonary artery pressures obtained through a tiny, permanent wireless implant had a 30 percent reduction in hospitalization rates at six months.
June 1, 2010 โ A teleproctoring technology uses robotic technology to teach physicians about new procedures without the additional expense of travel.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
June 1, 2010 โ A quadripolar pacing system was recently released in Europe and offers physicians the ability to more effectively manage the ever-changing pacing needs of patients with heart failure.
June 1, 2010 โ A home sleep testing technology eliminates the need for hospital sleep lab testing, instead monitoring patients in their own beds. The Nihon Kohden Nomad is a type III wearable portable recording device. It offers the ability to record 2 effort, 2 flow, snoring, body position, SpO2, heart rate and leg movements in a lightweight durable casing.
May 27, 2010 โ A single catheter combining both intravascular ultrasound (IVUS) and near-infrared (NIR) spectroscopy to identify lipid-core plaques (LCP) was unveiled at EuroPRC in Paris this week. The device also was demonstrated in live patient cases.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
May 27, 2010 โ Positive results from CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) will be used to expand the U.S. Food and Drug Administration (FDA) indication for carotid stents.
May 27, 2010 โ The first patient was recently enrolled in the ORBIT II investigational device exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360 atherectomy system in treating calcified coronary arteries.
May 27, 2010 โ One-year data presented this week at EuroPCR in Paris confirms sustained clinical outcomes with Cook Medical's drug-eluting peripheral stent, Zilver PTX.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
May 27, 2010 โ New European data from five national clinical registries presented this week at EuroPCR in Paris report positive clinical outcomes for the transcatheter aortic valve implantation for treatment of severe aortic stenosis.
May 26, 2010 โ The first angioplasty balloon catheter to integrate intravascular ultrasound (IVUS) imaging has gained CE-mark clearance in Europe. Volcano Corp. also announced today it completed its first clinical cases with the Vibe RX catheter in New Zealand.
May 26, 2010 โ In the constantly evolving battle for the best coronary stent, Boston Scientific said today it initiated the PLATINUM PLUS clinical trial, comparing its next-generation Promus Element everolimus-eluting coronary stent to the Xience Prime everolimus-eluting coronary stent.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
May 26, 2010 โ The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with bioresorbable drug polymer to reduce tissue/polymer contact, demonstrated excellent safety and efficacy outcomes. The results from the NEVO RES-I clinical trial were presented yesterday at EuroPCR in Paris.
May 25, 2010 โ A balloon catheter technology with enhanced trackability and a redesigned tip for greater flexibility was recently cleared by the U.S. Food and Drug Administration (FDA) and received European CE mark.
May 25, 2010 โ A clinical trial will examine benefits of fractional flow reserve (FFR)-guided stenting with optimal medical treatment compared to medical treatment alone. The FAME II clinical trial, the follow-up to the landmark FAME trial, recently started enrolling patients.